<DOC>
	<DOCNO>NCT01029340</DOCNO>
	<brief_summary>The study ass pharmacokinetics ( part A ) safety , tolerability , efficacy prophylaxis treatment ( 2 3 time week ) ( part B ) BAY81-8973 one year period ( split two six month treatment period ) . The study compare 2 different method ( assay ) measure amount study drug , chromogenic substrate assay per European Pharmacopeia ( CS/EP ) classical assay ( Chromogenic Substrate Adjusted , CS/ADJ ) . During one six month period patient receive study drug dose measure use '' ( CS/EP ) six month period dose measure base Chromogenic Substrate Adjusted assay CS/ADJ )</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety New Full Length Recombinant Human FVIII Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male , age 12 65 year Severe hemophilia A define &lt; 1 % FVIII : C &gt; /= 150 day previous treatment FVIII lifetime Currently receive ondemand type prophylaxis treatment regimen FVIII product No history current FVIII inhibitor Presence another bleed disease different hemophilia A ( e.g. , von Willebrand disease , hemophilia B ) Low platelet count , abnormal kidney function , liver disease Received treatment immune suppress drug within last 3 month prior require treatment study . ( Some drug hepatitis C , Human immunodeficiency virus ( HIV ) , steroid allow ) Receiving receive experimental drug within 3 month prior study entry Allergy Factor VIII hamster mouse protein</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>